ADPT vs. FLDM, KOD, RXRX, KYMR, BEAM, FUSN, INBX, SANA, NMRA, and VIR
Should you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Fluidigm (FLDM), Kodiak Sciences (KOD), Recursion Pharmaceuticals (RXRX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), and Vir Biotechnology (VIR). These companies are all part of the "medical" sector.
Adaptive Biotechnologies (NASDAQ:ADPT) and Fluidigm (NASDAQ:FLDM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
In the previous week, Adaptive Biotechnologies had 8 more articles in the media than Fluidigm. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 0 mentions for Fluidigm. Adaptive Biotechnologies' average media sentiment score of 0.50 beat Fluidigm's score of 0.28 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.
Adaptive Biotechnologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
Fluidigm has a net margin of -45.36% compared to Adaptive Biotechnologies' net margin of -123.24%. Fluidigm's return on equity of -40.15% beat Adaptive Biotechnologies' return on equity.
Fluidigm received 425 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 65.57% of users gave Fluidigm an outperform vote while only 56.52% of users gave Adaptive Biotechnologies an outperform vote.
Adaptive Biotechnologies currently has a consensus target price of $6.80, suggesting a potential upside of 97.10%.
99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 76.6% of Fluidigm shares are held by institutional investors. 6.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.9% of Fluidigm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Fluidigm has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks.
Summary
Adaptive Biotechnologies beats Fluidigm on 8 of the 15 factors compared between the two stocks.
Get Adaptive Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptive Biotechnologies Competitors List
Related Companies and Tools
